Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness?
- Investors may be wondering whether Haemonetics at US$58.46 is starting to look interesting on value, or if the market is still unsure what it is worth.
- The stock has returned 6.4% over the last 7 days, while the 30 day and year to date returns are an 8.8% decline and a 26.9% decline. The 1 year return is a 0.8% decline and the 3 year and 5 year returns are a 30.2% and 49.9% decline.
- These mixed returns have kept attention on how the market is pricing Haemonetics and what is driving investor sentiment. Ongoing coverage of the company keeps valuation front and center for readers who want a consistent reference point, regardless of short term news flow.
- Haemonetics currently has a valuation score of 6/6. Next up is a look at how different…
Source link
